GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Financiere de Tubize TUB.BR · EUR

Health Care · Euronext Brussels · 🇧🇪 Belgium

Compare

246.00

+2.50%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Financiere de Tubize

Its shares trade on Euronext Brussels under the ticker TUB.BR. It has been listed since 2 January 1987. In the fiscal year to 31 December 2024, it reported net income of €90.1m. At that date it held total assets of €1.93bn and shareholders' equity of €1.84bn.

Financiere de Tubize SA is a holding company, which engages in investing in biopharmaceuticals industry. The company is headquartered in Brussels, Bruxelles-Capitale. The firm holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
2 Jan 1987

Leadership

Pay as last reported

  • Prof. Dr. Bruno HolthofIndependent Chairman of the Board€6,000
  • Mr. Eric CornutDirector€5,000
  • Ms. Cynthia d'EchallensDirector€6,000
  • Mrs. Evelyn Diego Du Monceau De BergendalDirector, since 2015€6,000
  • Mr. Tanguy du MonceauDirector - Representative of Bergendal and Co SRL€5,000
  • Mr. Charles-Antoine JanssenDirector - Representative of BLTB SRL€6,000
  • Mr. Cyril JanssenDirector - Representative of Nikita SRL€5,000
  • Mr. Cedric van RijckevorselDirector - Representative of AlgoScient SARL€6,000
  • Ms. Sandrine FloryIndependent Director€4,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
6
Environment
7
Social
3
Governance
8
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Financiere de Tubize SA holds minor capital in UCB SA.
  • UCB SA specializes in diseases of the central nervous system.
  • UCB SA operates in the immunology therapeutic area.

Weaknesses

  • Financiere de Tubize SA is a holding company with limited direct operations.
  • The firm holds only minor capital in UCB SA.
  • Financiere de Tubize SA relies heavily on its investment in UCB SA.

Opportunities

  • UCB SA has research facilities in Germany and Japan.
  • UCB SA conducts research in the United Kingdom and the United States.
  • UCB SA expands its presence in the global biopharmaceuticals industry.

Threats

  • UCB SA faces competition in the central nervous system market.
  • UCB SA operates in the highly regulated pharmaceuticals industry.
  • Financiere de Tubize SA is exposed to UCB SA performance risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.